全文获取类型
收费全文 | 10480篇 |
免费 | 623篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 189篇 |
妇产科学 | 281篇 |
基础医学 | 1622篇 |
口腔科学 | 115篇 |
临床医学 | 956篇 |
内科学 | 2000篇 |
皮肤病学 | 268篇 |
神经病学 | 1136篇 |
特种医学 | 523篇 |
外科学 | 1637篇 |
综合类 | 39篇 |
一般理论 | 1篇 |
预防医学 | 412篇 |
眼科学 | 181篇 |
药学 | 766篇 |
中国医学 | 8篇 |
肿瘤学 | 910篇 |
出版年
2022年 | 70篇 |
2021年 | 131篇 |
2020年 | 108篇 |
2019年 | 149篇 |
2018年 | 169篇 |
2017年 | 166篇 |
2016年 | 215篇 |
2015年 | 212篇 |
2014年 | 288篇 |
2013年 | 370篇 |
2012年 | 501篇 |
2011年 | 623篇 |
2010年 | 384篇 |
2009年 | 391篇 |
2008年 | 600篇 |
2007年 | 666篇 |
2006年 | 631篇 |
2005年 | 638篇 |
2004年 | 626篇 |
2003年 | 596篇 |
2002年 | 546篇 |
2001年 | 245篇 |
2000年 | 232篇 |
1999年 | 205篇 |
1998年 | 139篇 |
1997年 | 133篇 |
1996年 | 99篇 |
1995年 | 91篇 |
1994年 | 71篇 |
1993年 | 81篇 |
1992年 | 131篇 |
1991年 | 120篇 |
1990年 | 108篇 |
1989年 | 104篇 |
1988年 | 85篇 |
1987年 | 62篇 |
1986年 | 64篇 |
1985年 | 86篇 |
1984年 | 55篇 |
1983年 | 72篇 |
1982年 | 42篇 |
1981年 | 53篇 |
1980年 | 42篇 |
1979年 | 61篇 |
1978年 | 51篇 |
1977年 | 49篇 |
1976年 | 47篇 |
1975年 | 38篇 |
1974年 | 38篇 |
1973年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
2.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
3.
4.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
5.
6.
7.
8.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
9.
We evaluated the acquisition and performance of a high-precision locomotor task in patients with Parkinson's disease (PD) and healthy subjects. All subjects walked on a treadmill and had to step repetitively as low as possible over an obstacle without touching it. During blocks 1 and 2, the subjects had full vision and received additional acoustic warning and feedback signals. During block 3, vision became restricted. Changes in foot clearance and the number of obstacle hits were evaluated. Initially, PD patients performed poorer and improved foot clearance slower. After task repetition, the groups performed similarly. Restricting vision deteriorated performance in both groups. The similar performance of PD patients after task repetition might indicate that adequate training could improve adaptive locomotor behavior in PD patients. 相似文献
10.
J M Esteban J A Kuhn B Felder J Y Wong H Battifora J D Beatty P M Wanek J E Shively 《Cancer research》1991,51(14):3802-3806
We have previously shown that the colon carcinoma (LS174T) xenografts that emerged shortly after radioimmunotherapy with 90Y-labeled anti-CEA monoclonal antibody (MAb) ZCE025 lacked significant expression of CEA in comparison with the untreated tumors. The present study was designed to establish if the immunophenotype of the treated tumors was the result of CEA specific therapy and if the effect was permanent. Athymic mice bearing LS174T tumors were treated either with 120 mu Ci of 90Y-ZCE025, an equal dose of 90Y-96.5 (nonspecific MAb), or received no treatment. When the treated tumors grew to approximately 1.5 cm in diameter (6 weeks after therapy), they were resected and aliquoted to be transplanted to other mice, plated in tissue culture, fixed in formalin, and homogenized for CEA quantitation. The procedure was repeated 3 times (a total of 4 months after treatment). The CEA content was evaluated 2 and 6 weeks after therapy and when the tumors were transplanted. We confirmed a 4-fold decrease of CEA in the resurgent tumors 6 weeks after specific 90Y-ZCE025 therapy, which was twice the decrease experienced by the tumors treated with nonspecific 90Y-96.5, indicating substantial and specific killing of CEA-expressing cells. The CEA content slowly but progressively increased with each new pass of the tumor in the mice, reaching approximately one-half the value of the controls at the end of the study. The resurgent tumors were also studied by immunohistochemistry with MAbs detecting different epitopes of CEA, keratin, TAG-72, and epithelial membrane antigen to evaluate possible additional immunophenotypic changes induced by radioimmunotherapy. Only the expression of TAG-72 (recognized by MAb B72.3) increased immediately after therapy, but it returned to the original levels by the end of the study. These results suggest that: (a) specific radioimmunotherapy with 90Y-ZCE025 selectively kills cells that express higher levels of CEA; (b) the immunophenotype of the surviving fraction of the tumor appears to slowly revert to its original form; and (c) other tumor markers unrelated to CEA can also be affected. These observations have important implications for the design of radioimmunotherapy trials. 相似文献